Imugene’s Australian Trial for Innovative Cancer Therapy Begins
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2025
0mins
Should l Buy ?
Source: Business Insider
Imugene Limited's Trial Update: Imugene Limited has initiated the dosing of the first Australian patient in its Phase 1b trial for azer-cel, an allogeneic CAR T-cell therapy targeting relapsed or refractory diffuse large B-cell lymphoma at Royal Prince Alfred Hospital in Sydney.
Positive Outlook for Expansion: Following successful results from US trials indicating complete responses, Imugene is optimistic about expanding the trial across Australia.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
